HLA-A and hepatocellular carcinoma: Furthermore, MAGE‐A1 and NY‐ESO‐1 are aberrantly expressed and immunogenic in a variety of malignancies.17 Therefore, we included 37 patients with HCC (25 HLA‐A*02+, 10 HLA‐A*03+, and two HLA‐A*02+/A*03+) and in addition eight patients with melanoma (five HLA‐A*02+, two HLA‐A*03+, and one HLA‐A*02+/A*03+) as controls (Table 1).